Wednesday, February 14, 2007

AGEN & HEB

Here's a heads-up from Ilene, who likes AGEN for their technology and recent insider buying and HEB in light of some interesting news:


from Ilene:


Interesting news item from HEB - also working on bird flu, but with tech. that would apply to various viral diseases as well.

Hemispherx Avian Flu Prevention/Treatment Program Announces New Primate Results and Expands in both Europe and Southern Hemisphere

Wednesday February 14, 1:18 pm ET

Experimental Treatment Designed to Prevent/Treat Multiple H5N1 Classes with Oral Non-Toxic Treatment


PHILADELPHIA--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX:HEB - News) announced today initial results of a new primate treatment program with Viroclinics, based in the Netherlands, and directed by Professor Albert Osterhaus, a world authority in Avian influenza spread and prevention.
In the primate study, macaque monkeys were pre-treated orally (sublingually) with either Alferon-N (a proprietary formulation of 8 molecular types of human alpha interferon) or placebo. Thereafter, they were exposed to highly pathogenic avian influenza virus, strain H5N1, which has resulted to date in a greater than 60% death rate in humans. Control animals, as expected, shown massive pneumonia by both gross and microscopic examination which was greatly ameliorated by treatment with Alferon LDO (applied sublingually).

The Hemispherx Vaccine Enhancement(TM) Platform is the utilization of Alferon LDO (derived from an FDA licensed therapeutic for another virus, HPV) via the Viroclinics collaboration based on promising results in a human volunteer study recently conducted in Hong Kong.

Based on earlier primate studies reported by the independent Japanese Institute of Infectious Diseases (JIID), collaborating with Hemispherx, the addition of Hemispherx's second experimental therapeutic, Ampligen®, may also provide vaccine cross-protection against different H5N1 strains when co-administered with a influenza vaccine.

In the expanded Australian clinical trial, studies will determine whether seasonal vaccine co-administered with the experimental therapeutic Ampligen®, may provide long-lasting seroprotection against either/both of the emerging strains of H5N1. The level of measured immune response to provide adequate protection in humans is as yet unknown, however, primate and lower animal research conducted by the JIID suggest that broad based cross protection in man by a single therapeutic treatment (Ampligen®), acting as a "TLR3 agonist" (stimulator) may be sufficient.

The U.S. Department of Health and Human Services (HHS) has recently announced a new pre-pandemic vaccine procurement program out of concern that the existing vaccine "won't work well" against the newer pandemic strains now spreading thru birds in China, Indonesia (2004), the Middle East, Europe and Africa (2006) and Great Britain (2007).

Based on these overall positive results, the Company has initiated active discussions with the U.S. Department of Defense regarding its biopreparedness, biodefense initiatives and priorities.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection® and the experimental therapeutics Ampligen® and Oragens®. Alferon N Injection® is approved for a category of STD infection, and Ampligen® and Oragens® represent experimental RNA nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection®) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

5 comments:

Anonymous said...

Champions Biotechnology, Inc. Acquires Rights to Cancer Drug Candidates
ARLINGTON, Va., Feb. 14 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC: CSBR) (BULLETIN BOARD: CSBR) , a development stage biotechnology company, announced today the acquisition of patent rights encompassing two Benzoylphenylurea (BPU) sulfur analog compounds that have shown promising potent activity against prostate and pancreatic cancer cell lines (Journal of Medicinal Chemistry, 2006, Vol. 49, No.7, 2357-2360). The acquired rights include pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.

These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau) deficient tumors, a common feature of solid tumors, and have performed better than Docetaxel (Taxotere) in the difficult to treat direct patient xenograft models of pancreatic cancer (Journal of the National Cancer Institute, Vol. 99, Issue 2, January 17 2007, 105-107). The Company, in exchange for 550,000 restricted shares of its common stock, was assigned all the rights in the U.S. and in foreign countries to the applications for these inhibitors developed at Johns Hopkins University by their inventors Drs. Saeed Khan, Gurulingappa Hallur, Manuel Hidalgo and Antonio Jimeno.

This acquisition is the Company's initial step in building a biotechnology company from the ground up with a future portfolio of possible therapeutic drug candidates among other ventures that it is actively exploring. The Company plans to develop candidates from its portfolio of therapeutic compounds and partner with pharmaceutical and/or biotechnology partners for development, regulatory approval and marketing as appropriate.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. The Company generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors, which may include, but are not limited to, changes in general economic conditions, the ongoing threat of terrorism, ability to have access to financing sources on reasonable terms and other risks that are described in this document. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and the Company's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company's expectations, except as required by law.

Anonymous said...

My recent purchase of CBMX as part of my RNA Interferrence basket was rewarded today. Also CYTR is doing well.

Greg Reiman

Anonymous said...

CSBR formerly operated as a sports bar? Strange beginnings for biotech company?

Anonymous said...

How about XDSL lately!!

Anonymous said...

DIGL.ob is rocketing.

http://biz.yahoo.com/t/43/702.html